UA66809C2 - Method for treatment of hyperglycaemia - Google Patents

Method for treatment of hyperglycaemia

Info

Publication number
UA66809C2
UA66809C2 UA2000042049A UA00042049A UA66809C2 UA 66809 C2 UA66809 C2 UA 66809C2 UA 2000042049 A UA2000042049 A UA 2000042049A UA 00042049 A UA00042049 A UA 00042049A UA 66809 C2 UA66809 C2 UA 66809C2
Authority
UA
Ukraine
Prior art keywords
hyperglycaemia
treatment
mammal
pharmaceutically acceptable
need
Prior art date
Application number
UA2000042049A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Робін Едвін Букінгем
Стефен Елістер Сміт
Original Assignee
Смітклайн Бічам Плс
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смітклайн Бічам Плс, Смитклайн Бичам Плс filed Critical Смітклайн Бічам Плс
Publication of UA66809C2 publication Critical patent/UA66809C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A method for the treatment of hyperglycaemia wherein plasma glucose levels in the range of from > 126 mg/dl to 140 mg/dl, which method comprises administering an effective nontoxic and pharmaceutically acceptable amount of an insulin sensitizer, to a mammal in need thereof.
UA2000042049A 1997-10-13 1998-10-12 Method for treatment of hyperglycaemia UA66809C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721692.3A GB9721692D0 (en) 1997-10-13 1997-10-13 Novel treatment
PCT/GB1998/003067 WO1999018944A1 (en) 1997-10-13 1998-10-12 Use of thiazolidinediones for the treatment of hyperglycaemia

Publications (1)

Publication Number Publication Date
UA66809C2 true UA66809C2 (en) 2004-06-15

Family

ID=10820481

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000042049A UA66809C2 (en) 1997-10-13 1998-10-12 Method for treatment of hyperglycaemia

Country Status (24)

Country Link
EP (1) EP1023057A1 (en)
JP (1) JP2001519383A (en)
KR (1) KR20010024482A (en)
CN (1) CN1281358A (en)
AP (1) AP1223A (en)
AU (1) AU9547198A (en)
BG (1) BG104405A (en)
BR (1) BR9815220A (en)
CA (1) CA2305289A1 (en)
CZ (1) CZ20001298A3 (en)
EA (1) EA200000418A1 (en)
GB (1) GB9721692D0 (en)
HR (1) HRP20000256A2 (en)
HU (1) HUP0003673A3 (en)
ID (1) ID24439A (en)
IL (1) IL135515A0 (en)
NO (1) NO20001897L (en)
OA (1) OA11519A (en)
PL (1) PL339804A1 (en)
SK (1) SK5322000A3 (en)
TR (1) TR200000957T2 (en)
UA (1) UA66809C2 (en)
WO (1) WO1999018944A1 (en)
YU (1) YU28700A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200100207T2 (en) * 1998-07-21 2001-05-21 Smithkline Beecham P.L.C. The use of substance enhancing glucose uptake for the reduction of apoptosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus

Also Published As

Publication number Publication date
AP1223A (en) 2003-11-13
AU9547198A (en) 1999-05-03
JP2001519383A (en) 2001-10-23
HRP20000256A2 (en) 2000-12-31
EA200000418A1 (en) 2000-10-30
GB9721692D0 (en) 1997-12-10
SK5322000A3 (en) 2000-09-12
CZ20001298A3 (en) 2001-08-15
NO20001897D0 (en) 2000-04-12
HUP0003673A3 (en) 2001-12-28
NO20001897L (en) 2000-06-09
YU28700A (en) 2003-10-31
TR200000957T2 (en) 2000-08-21
WO1999018944A1 (en) 1999-04-22
CN1281358A (en) 2001-01-24
BG104405A (en) 2000-12-29
KR20010024482A (en) 2001-03-26
ID24439A (en) 2000-07-20
PL339804A1 (en) 2001-01-02
CA2305289A1 (en) 1999-04-22
BR9815220A (en) 2000-11-14
AP2000001788A0 (en) 2000-06-30
IL135515A0 (en) 2001-05-20
EP1023057A1 (en) 2000-08-02
OA11519A (en) 2004-02-09
HUP0003673A2 (en) 2001-10-28

Similar Documents

Publication Publication Date Title
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
EP1127579A3 (en) Method for increasing bioavailability of oral pharmaceutical compositions
WO2000016762A3 (en) Method for reducing nicotine dependency
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
EP1574219A3 (en) Method of inhibiting fibrosis with a somatostatin agonist
NZ514574A (en) Novel method of treatment
MXPA03003870A (en) Combination therapy comprising anti-diabetic and anticonvulsant agents.
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
CA2329004A1 (en) Combination of insulin sensitizer with anorectic for treating or preventing diabetes
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
EP1576956A3 (en) Chromium/biotin treatment of type II diabetes
CA2339218A1 (en) Methods and compositions for increasing insulin sensitivity
WO1999004772A3 (en) Use of levobupivacaine
CA2253130A1 (en) A medicament for treating obesity and improving lipid metabolism
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
BG101884A (en) Salts of the clavulanic acid
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
UA66809C2 (en) Method for treatment of hyperglycaemia
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
NZ503862A (en) Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia
MX9604692A (en) Quinoxaline derivatives for treating tinnitus.